Clinical Trials from A to Z - Risks and Benefits - Part 2 of 4
Links shared publicly online about this topic.
- 504total visits
Clinical Trials from A to Z - Risks and Benefits - Part 2 of 4
View full resource at spineuniverse.com
Tags: Drug, Clinical Trial
Most Recently Shared on February 15, 2011 at 8:20 pm By:
Clinical Trials from A to Z - Risks and Benefits http://dlvr.it/GgYQ4
Five-year Alemtuzumab Phase 2 Data Shows Large Percentage of MS Patients Remain Free of Clinically-Active Disease | Business Wire
businesswire.com — “Genzyme reports additional five-year patient data from its completed Phase 2 multiple sclerosis trial showing that a large percentage of MS patients r” View full resource at businesswire.com
Most Recently Shared on April 14, 2011 at 4:13 pm By:
eyeonfda Pharma and Health Lawyer
Five-year Genzyme Alemtuzumab Phase 2 Data treatment of #MS Patients http://ow.ly/4Ai9Z
ZymoGenetics Reports Favorable Survival Data from IL-21 Phase 2a Clinical Trial in Melanoma - Drugs.com MedNews
drugs.com — “Median overall survival of 12.4 months Sep 29, 2010 - ZymoGenetics, Inc. (NASDAQ ZGEN) today announced positive survival data from a Phase 2a clinical trial in” View full resource at drugs.com
Most Recently Shared on September 29, 2010 at 8:09 pm By:
Drugs and Devices OW OW Health
ZymoGenetics Reports Favorable Survival Data from IL-21 Phase 2a Clinical Trial in Melanoma: Median overall s... http://bit.ly/b1v3z3 #drug
CPEX Pharmaceuticals Announces Preliminary Results From Its Phase 2a Clinical Trial Of Nasulin™
medicalnewstoday.com — “CPEX Pharmaceuticals Inc. (NASDAQ: CPEX) reported preliminary results related to its Phase 2a proof-of-concept clinical trial of the Company's nasal insulin product, Nasulin™. The study was” View full resource at medicalnewstoday.com
Most Recently Shared on March 19, 2010 at 12:43 pm By:
Scott Strumello Patient Expert
"CPEX Pharmaceuticals Announces Preliminary Results From Its Phase 2a Clinical Trial Of Nasulinâ„¢": http://bit.ly/bFYRw4
Cetuximab in Early-Stage Colon Cancer Shows No Benefit - National Cancer Institute
cancer.gov — “A Data Monitoring Committee (DMC) determined that in a phase 3 clinical trial for early-stage colon cancer, no group of patients benefited from the addition of the monoclonal antibody cetuximab (ErbituxTM) to a standard chemotherapy regimen known as FOLFO” View full resource at cancer.gov
Most Recently Shared on December 2, 2009 at 7:07 pm By:
NCI News: Addition of Cetuximab 2 Standard Chemo 4 Early-Stage Colon Cancer Shows No Benefit-Phase 3 Trial http://j.mp/8eqZP3
Interim Data From A Clinical Trial Evaluating GI Dynamics' EndoBarrier™ Gastrointestinal Liner In Patients With Type 2 Diabetes
medicalnewstoday.com — “GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, announced that interim data from its ongoing clinical study of the EndoBarrier™ Gastrointestina” View full resource at medicalnewstoday.com
Most Recently Shared on November 25, 2009 at 9:35 am By:
Interim Data From A Clinical Trial Evaluating GI Dynamics' EndoBarrier™ Gastrointestinal Liner In Patien.. http://bit.ly/4Z2ENd
Affymax And Takeda Announce Hematide™ Publication In The New England Journal Of Medicine
medicalnewstoday.com — “Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceutical Global Research & Development Center, Inc., announced data from a Phase 2 clinical trial of Hematide™ showing that Hematide increased he” View full resource at medicalnewstoday.com
Most Recently Shared on November 6, 2009 at 12:34 am By:
MNT Clinical Trials Health News
Affymax And Takeda Announce Hematide™ Publication In The New England Journal Of Medicine: Affymax, Inc. .. http://bit.ly/4zpS8Q
Advertisement
